|
Jun 25
|
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
|
|
Jun 20
|
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
|
|
Mar 21
|
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
|
|
Aug 9
|
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates
|
|
Aug 8
|
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
|